A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

A Clinical Phase 1 Safety And Pharmacokinetic/Pharmacodynamic Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

To evaluate safety and tolerability of PF-00299804 in Japanese patients with advanced malignant solid tumors at doses up to the clinically recommended phase 2 dose in non-Japanese studies.

Inclusion Criteria:

• Malignant solid tumor with no currently approved treatment
• Adequate functions Bone Marrow, Renal, Liver and Cardiac

Exclusion Criteria:

• Any surgery, radiotherapy within 4 weeks of baseline disease assessments
• Clinically significant abnormalities of the cornea
• Patients with symptomatic brain/central nerve system metastases
• Any clinically significant gastrointestinal abnormalities
• Uncontrolled or significant cardiovascular disease
• Patients with significant interstitial pneumonia or pulmonary fibrosis